Get the Stockscreener App
20.85
4.77%
0.95
After Hours:
20.85
Dianthus Therapeutics Inc stock is traded at $20.85, with a volume of 242.44K.
It is up +4.77% in the last 24 hours and up +3.94% over the past month.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
See More
Previous Close:
$19.90
Open:
$20.01
24h Volume:
242.44K
Relative Volume:
0.76
Market Cap:
$670.54M
Revenue:
$4.12M
Net Income/Loss:
$-56.68M
P/E Ratio:
-3.7616
EPS:
-5.5429
Net Cash Flow:
$-51.44M
1W Performance:
+2.26%
1M Performance:
+3.94%
6M Performance:
-13.59%
1Y Performance:
-21.23%
1-Day Range:
$19.75
$21.18
1-Week Range:
$18.08
$21.18
52-Week Range:
$13.37
$32.27
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Name
Dianthus Therapeutics Inc
Sector
Industry
Phone
929-999-4055
Address
7 TIMES SQUARE, NEW YORK
Compare DNTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
20.85 | 640.55M | 4.12M | -56.68M | -51.44M | -5.5429 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-02-25 | Initiated | William Blair | Outperform |
| Dec-20-24 | Initiated | TD Cowen | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-26-24 | Initiated | Robert W. Baird | Outperform |
| Jun-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-24 | Initiated | H.C. Wainwright | Buy |
| Feb-15-24 | Initiated | Stifel | Buy |
| Dec-26-23 | Initiated | Jefferies | Buy |
| Nov-22-23 | Initiated | Wedbush | Outperform |
| Oct-30-23 | Initiated | Guggenheim | Buy |
| Sep-28-23 | Initiated | Raymond James | Outperform |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-06-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-20-21 | Resumed | Goldman | Neutral |
| Aug-03-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-21 | Reiterated | B. Riley Securities | Buy |
| Jun-29-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-18-21 | Initiated | B. Riley Securities | Buy |
| Jan-07-21 | Initiated | Mizuho | Buy |
| Jun-08-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-25-19 | Downgrade | Goldman | Buy → Neutral |
| Mar-15-19 | Initiated | Raymond James | Outperform |
View All
Dianthus Therapeutics Inc Stock (DNTH) Latest News
Is this a good reentry point in Dianthus Therapeutics Inc.Sell Signal & Stock Market Timing Techniques - Newser
Dianthus Therapeutics Inc.’s volatility index tracking explainedAnalyst Upgrade & Growth Oriented Trading Recommendations - Newser
Dianthus Therapeutics Inc. stock trend forecast2025 Year in Review & Real-Time Stock Entry Alerts - Newser
What earnings revisions data tells us about Dianthus Therapeutics Inc.2025 Key Lessons & Breakout Confirmation Alerts - Newser
How to forecast Dianthus Therapeutics Inc. trends using time seriesMarket Growth Review & Consistent Profit Focused Trading Strategies - Newser
Can trapped investors hope for a rebound in Dianthus Therapeutics Inc.Long Setup & Technical Entry and Exit Alerts - Newser
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $53.00 Consensus Target Price from Brokerages - MarketBeat
Backtesting results for Dianthus Therapeutics Inc. trading strategiesWeekly Stock Recap & Precise Entry and Exit Recommendations - Newser
Can you recover from losses in Dianthus Therapeutics Inc. [Quarterly Performance Summary]Free Reliable Trade Execution Plans - Newser
How institutional ownership impacts Dianthus Therapeutics Inc. stock [July 2025 Rallies]Free Community Verified Trade Signals - Newser
Is Dianthus Therapeutics Inc. stock poised for growthFree Weekly Setup With 3x Return Potential - Newser
Custom watchlist performance reports with Dianthus Therapeutics Inc.Strong Buy Opportunity with Volume Support - Newser
What is William Blair's Estimate for DNTH Q1 Earnings? - MarketBeat
Relative strength of Dianthus Therapeutics Inc. in sector analysisDay Trading Plan with Entry Risk Management - Newser
Has Dianthus Therapeutics Inc. formed a bullish divergenceDay Trading Setup and Momentum Analysis - Newser
How moving averages guide Dianthus Therapeutics Inc. tradingFree Triple Return Setup with Risk Control - Newser
How institutional ownership impacts Dianthus Therapeutics Inc. stockDaily Profit Watch With Forecast Confidence - Newser
Will earnings trigger a reversal in Dianthus Therapeutics Inc.Predictable Income Summary for Long-Term Trades - Newser
Dianthus Therapeutics (DNTH) to Release Earnings on Thursday - MarketBeat
Key External Factors That Drive Dianthus Therapeutics Inc. Stock Price MovementsValue Holding Return Summary With Outlook - Newser
Real time breakdown of Dianthus Therapeutics Inc. stock performancePortfolio Risk Summary & Technical Entry and Exit Alerts - Newser
Why Dianthus Therapeutics Inc. stock attracts strong analyst attentionFree Accurate Buy Point for Momentum Stocks - Newser
What makes Dianthus Therapeutics Inc. stock price move sharplyFree Consistent Gain Investment Strategies - Newser
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Is Dianthus Therapeutics Inc. still worth holding after the dipFree Reliable Investment Entry Point Signals - Newser
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Lags Revenue Estimates - NewsBreak: Local News & Alerts
Dianthus Therapeutics Reports Q2 2025 Financial Results - TipRanks
Earnings Preview: Dianthus Therapeutics, Inc. (DNTH) Q2 Earnings Expected to Decline - NewsBreak: Local News & Alerts
Dianthus Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Promising Outlook for Dianthus Therapeutics: Buy Rating on Claseprubart’s Potential in gMG - TipRanks
Dianthus Therapeutics: Promising Prospects with DNTH103 and Strong Financial Position Support Buy Rating - TipRanks
Dianthus (DNTH) Q2 Loss Widens 80% - AOL.com
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results - The Manila Times
Dianthus Therapeutics Nears Critical Phase 2 Trial Results: $309M Cash Runway Powers Multiple Clinical Programs - Stock Titan
Dianthus Therapeutics (DNTH) Expected to Announce Earnings on Thursday - Defense World
Dianthus Therapeutics Inc Stock (DNTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):